Endocyte, Inc. (NASDAQ:ECYT) Ratings Summary on May 16, 2018

May 16, 2018 - By Mary Bollinger

During Q4 2017 the big money sentiment increased to 1.36. That’s change of 1.04, from 2017Q3’s 0.32. 11 investors sold all, 14 reduced holdings as Endocyte, Inc. ratio is positive. 15 rose stakes while 19 funds took stakes. Funds hold 19.91 million shares thus 140.76% more from 2017Q3’s 8.27 million shares.
Moreover, California Employees Retirement Sys has 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 258,100 shs. Citigroup Inc owns 1,513 shs. 241,498 are held by Geode Mgmt Lc. Bankshares Of America Corp De has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Gemmer Asset Mngmt Limited Liability Co invested in 0% or 1,500 shs. 525 are held by Fin Architects Inc. Gru One Trading Limited Partnership invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Parallax Volatility Advisers Limited Partnership, California-based fund reported 7,613 shs. Spark Inv Management Ltd Company holds 57,200 shs. D E Shaw Com has invested 0.01% in Endocyte, Inc. (NASDAQ:ECYT). Manufacturers Life Communication The holds 0% in Endocyte, Inc. (NASDAQ:ECYT) or 1,801 shs. Fincl Bank Of New York Mellon has invested 0% of its capital in Endocyte, Inc. (NASDAQ:ECYT). Proshare Advisors Limited Liability Co stated it has 0% of its capital in Endocyte, Inc. (NASDAQ:ECYT). Hilltop Hldgs holds 0.01% or 10,720 shs. Reilly Fin Ltd Com owns 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 2,000 shs.

Endocyte, Inc. had 1 insider sale and 0 insider buys since March 9, 2018. This’s net activity of $45,677.

Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage

Total analysts of 3 have positions in Endocyte (NASDAQ:ECYT) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since February 27, 2018 according to StockzIntelligence Inc Endocyte has 3 analyst reports. On Tuesday, February 27 Cowen & Co upgraded Endocyte, Inc. (NASDAQ:ECYT) to “Outperform” rating. Listed here are Endocyte, Inc. (NASDAQ:ECYT) PTs and latest ratings.

13/04/2018 Broker: Jefferies Rating: Buy New Target: $17 Initiates Coverage On
09/03/2018 Broker: Wells Fargo Rating: Outperform New Target: $20 Initiates Coverage On
27/02/2018 Broker: Cowen & Co Old Rating: Market Perform New Rating: Outperform Upgrade

The stock increased 5.45% or $0.66 during the last trading session, reaching $12.77.Currently Endocyte, Inc. is uptrending after 296.90% change in last May 16, 2017. ECYT has 860,613 shares volume. The stock outperformed the S&P 500 by 285.35%.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.The firm is worth $880.74 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents.Last it reported negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

A couple more Endocyte, Inc. (NASDAQ:ECYT) news were announced by: Seekingalpha.com which released on May 09, 2018 “Endocyte’s (ECYT) CEO Mike Sherman on Q1 2018 Results – Earnings Call Transcript”, also Globenewswire.com on May 09, 2018 announced “Endocyte Provides First Quarter 2018 Financial Results and Operational Update”, the next Benzinga.com is “26 Stocks Moving In Monday’s Pre-Market Session” on May 14, 2018. Globenewswire.com has article titled “Endocyte Announces First Quarter 2018 Earnings Call”.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.